Skip to content

News

The Institute generates news every day. Some findings are groundbreaking—some represent smaller steps. But ultimately, it is the combination of both that makes scientific advancement possible. Here is a little selection of the latest stories making it out to the wider world.

Filter by:

Keyword

Showing

Funding for excellent research extended: LIT Scientists’ contribution is key in CRC/Transregio 221

27.01.2026

The German Research Foundation (DFG) has extended the Collaborative Research Center (CRC) Transregio 221 “Regulation of Graft-versus-Host and Graft-versus-Leukemia Immune Responses after Allogeneic Stem Cell Transplantation” for a third funding period of four years, committing 15 million euros in support to the participating partners. Researchers from the Leibniz Institute for Immunotherapy (LIT) play a key role in this large interdisciplinary research consortium and represent excellence in immunomedicine.

Kick-off for joint research projects at the interface of materials science and immunotherapy

22.01.2026

A delegation of scientists from the Leibniz Institute for Immunotherapy (LIT) recently visited the Leibniz Institute for New Materials (INM) in Saarbrücken. The aim of the meeting was to establish collaborations between the institutes in order to develop innovative forms of therapy at the interface between materials science and immunotherapy. There was particular interest in the topics of “synthetic cells,” “therapeutic Lactobacillus engineering,” and “optogenetic T-cell control.”

German Research Foundation DFG Extends Funding to Support Innovative T Cell Mitochondrial Research

21.01.2026

The Reinhart Koselleck project led by Prof. Luca Gattinoni and Dr. Jeremy Baldwin at the Leibniz Institute for Immunotherapy has received a highly positive interim report evaluation and has been awarded an additional €750,000 in funding to continue their pioneering research into the dynamic role of mitochondria in T-cell biology for the next two years. The decision reflects the exceptional scientific impact of the first funding phase and clears the way for the next stage of this ambitious research program.

Prof. Philipp Beckhove joins CDU “Netzwerk Wissenschaft”

13.01.2026

“Netzwerk Wissenschaft“, a new platform for developing ideas and putting them into practice, has been established by CDU Secretary General Dr. Carsten Linnemann and Prof. Dr. Hendrik Streeck, both Members of the German Bundestag. Prof. Philipp Beckhove, Scientific Director of the LIT, was invited to join the network and contribute his expertise.

LIT Researcher Awarded Prestigious Marie Skłodowska-Curie European Research Fellowship to Cambridge University

05.01.2026

The Marie Skłodowska-Curie Actions (MSCA) is the European Commission’s flagship program designed to support early-career researcher development and foster scientific excellence. Dr. Jeremy Baldwin’s research lies at the crossroads of immunology, synthetic biology and cancer research. During the upcoming fellowship, he will focus on engineering mitochondria for immunotherapy applications. His MSCA research proposal received a perfect score of 100.00% by EC evaluators – an exceptionally rare score achieved by less than 1% of the over 10,500 total MSCA applications.

Extension of SATURN3 Funding for Intratumoral Heterogeneity Research

16.12.2025

Since 2022, scientists at the LIT, led by Prof. Philipp Beckhove, Scientific Director and Head of Interventional Immunology Division, have been investigating intratumoral heterogeneity – the phenomenon that tumors undergo significant individual changes as the disease progresses – as part of the SATURN3 consortium. The Federal Ministry of Research, Technology and Space has extended this funding until June 2027 and increased it by around €220,000 to a total of nearly €600,000.

Podcast “Wirkstoffradio”: Interview with Dr. Markus Barden

15.12.2025

Dr. Markus Barden conducts research at the Leibniz Institute for Immunotherapy (LIT) in the Genetic-Immunotherapy Division, focusing in particular on how CAR T cells can recognize their target structures even more precisely. In the podcast “Wirkstoffradio”, he explains what a CAR T cell is, how T cells identify target structures, and what reactions follow.

How the LIT is developing tomorrow’s immunotherapies from Nobel Prize topics – Interview with Prof. Dr. Philipp Beckhove

12.12.2025

Prof. Dr. Philipp Beckhove, Scientific Director at the LIT, explains in an interview with the Science Blog of the University of Regensburg what influence Sakaguchi’s discovery of “peripheral” immune tolerance, in particular regulatory T cells (Tregs), had on immunology, how the collaboration with Shimon Sakaguchi came about, and how the new findings are paving the way for future immunotherapies.

Alzheimer’s Research Meets Art – Now Online

08.12.2025

The LIT was pleased to host „Alzheimer’s Research Meets Art“ – an Art Exhibition inspired by the Biomedical Research by Prof. Stefan Rüdiger.
For those who were unable to attend in person, we have now published photographs of the exhibited pieces accompanied by explanatory texts on our website.